StockVaultSandbox
ScreenerSectorsLearnMethodDesign
Request access
StockVaultSandbox
ScreenerSectorsLearnMethodDesign
Request access
Back to screenerCompare

LAURUSLABS — LAURUS LABS LIMITED

Price History

Data as of 26 Jun 2026· via fincrux

How LAURUSLABS has traded over time.

Is the price reasonable right now?

Where today's price sits within its own 12-month range — context, not advice.

Upper end of its 12-month range96% of range

Trading about 118% above its 12-month low and near recent highs — historically pricier territory for this stock. It sits above its 200-day average, the longer-term trend.

₹665 low₹1,481 high
vs 50-day avg
+11.6%
vs 200-day avg
+35.6%
Beginner mode
Plain English, with everything explained

LAURUSLABS

NSE

LAURUS LABS LIMITED

Healthcare / Pharma

₹1,450.00
0.00%
last close
0%
Quality Score
Looks high-qualityBig money selling

LAURUS LABS LIMITED clears 3 of 3 of our quality checks. By the numbers, it looks like a sturdy, well-run business at a fair price. Still your call — but this is the kind of company that doesn't rely on hype.

Company size
₹73528.00 Cr
Price tag
99.3×
Money it earns
15.1%

The four quality checks

Every company faces the same four checks. Tap the ? on any term to learn what it means.

01

Is the company drowning in loans?

We check how much the company has borrowed versus its own money. Too much debt makes a business fragile when times get tough.

Aligned

The company keeps its borrowing under control. That's a sign of a sturdy balance sheet.

D/E 0.40goal < 0.5
02

Does it make good money, consistently?

We look at how much profit the company squeezes out of its owners' money, averaged over three years — not just one lucky quarter.

Aligned

It turns its money into healthy profits year after year. A hallmark of a quality business.

ROE 15.1%goal > 15% (3y avg)
03

Is the big, smart money buying in?

Large professional investors (global funds and Indian mutual funds) do deep research before buying. We track whether they've been adding or trimming their stake.

Aligned

Professional investors have been holding steady or buying more — a quiet vote of confidence.

FII+DII 39.8%goal stable or rising (2Q)
04

Is the price reasonable right now?

Even a great company can be a bad buy if it's overpriced. We compare today's price tag to how this company has typically been priced over the past five years.

No data

We don't have enough reliable data to run this check yet, so we're leaving it open rather than guessing.

Data unavailablegoal P/E < 5y median

What we noticed

Observations from the data — not recommendations.

  • Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadershipposition in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs…
Data as of 26 Jun 2026· via fincrux

StockVault is an educational research and mathematical-modeling sandbox. It presents structural readings derived from public data and does not provide investment advice, recommendations, or target prices. Figures shown are illustrative and delayed. Markets carry risk; decisions are your own.

Balance Sheet

What LAURUSLABS owns and owes over the years. Tap the ? on any line to learn what it means.

Line itemFigures in ₹ crore
ItemMar '22Mar '23Mar '24Mar '25Mar '26
Borrowings1,6531,7142,1102,3802,080
Equity Capital107108108108108
Reserves3,2813,9494,0994,4565,144
Total Assets6,6096,9587,6678,5879,540
Total Liabilities6,6096,9587,6678,5879,540

Borrowings rising

Total borrowings are up about 26% over the last 5 years — worth watching alongside how much it earns.

Periodic Performance

Yearly net profit for LAURUSLABS — does it earn money consistently?

Potential turnaroundPotential turnaround (pattern in the data)

Profit dipped in the middle years and has been recovering in the most recent ones. That's a pattern in the data, not a forecast.

₹750 Cr
₹760 Cr
₹224 Cr
₹380 Cr
₹740 Cr
Mar '22Mar '23Mar '24Mar '25Mar '26
rev ₹4,707 Crrev ₹5,773 Crrev ₹4,812 Crrev ₹5,217 Crrev ₹6,089 Cr
Net profit · annualProfitLoss

Strengths & Risks

What the numbers say is good and bad about LAURUSLABS — observations, not recommendations.

Strengths

4
  • Turns owners' money into healthy profits, year after year.
  • Keeps borrowing low relative to its own capital — a sturdy balance sheet.
  • Large professional investors have been holding steady or adding to their stake.
  • Recent results show a return to profit after weaker years — a turnaround pattern in the data.

Risks

1
  • Sits near the top of its 12-month range — historically pricier territory for this stock.

Institutional Ownership Trend

FII and DII holding across the last four quarters.

FII· Foreign institutions
25.8%+0.1 pp
DII· Domestic institutions
14.0%+2.0 pp
Jun '25Sep '25Dec '25Mar '26

Sector Peers

How others in Healthcare / Pharma score on the same four guardrails.

  • DIVISLABDIVI S LABORATORIES LTD100
  • ALKEMALKEM LABORATORIES LTD.100
  • ZYDUSLIFEZYDUS LIFESCIENCES LTD100
  • IPCALABIPCA LABORATORIES LTD100
  • AJANTPHARMAJANTA PHARMA LIMITED100
View the full sector